Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies

Britt K. Erickson; Burak Zeybek; Alessandro D. Santin; Amanda N. Fader

doi:10.1097/GCO.0000000000000599

Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies

Britt K. Erickson, Burak Zeybek, Alessandro D. Santin, Amanda N. Fader

Obstetrics, Gynecology and Women's Health - Oncology

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Purpose of reviewThe purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers.Recent findingsApproximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated.SummaryHER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.

Original language	English (US)
Pages (from-to)	57-64
Number of pages	8
Journal	Current Opinion in Obstetrics and Gynecology
Volume	32
Issue number	1
DOIs	https://doi.org/10.1097/GCO.0000000000000599
State	Published - Feb 1 2020

Bibliographical note

Funding Information:
Research reported in this publication was supported to B.K.E. by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number K12HD055887 and to A.D.S. by R01 CA154460-01 and U01 CA176067-01A1 grants from NIH, the Deborah Bunn Alley Foundation, the Tina Brozman Foundation, the Discovery to Cure Foundation, the Guido Berlucchi Foundation, and the Stand-up-to cancer (SU2C) convergence grant 2.0 to A.D.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords

biomarker
human epidermal growth factor receptor 2
ovarian cancer
uterine serous carcinoma

Access

10.1097/GCO.0000000000000599

Fingerprint Dive into the research topics of 'Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies'. Together they form a unique fingerprint.

Cite this

@article{d82312873c624e42940e204f8d00b8f3,

title = "Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies",

abstract = "Purpose of reviewThe purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers.Recent findingsApproximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated.SummaryHER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.",

keywords = "biomarker, human epidermal growth factor receptor 2, ovarian cancer, uterine serous carcinoma",

author = "Erickson, {Britt K.} and Burak Zeybek and Santin, {Alessandro D.} and Fader, {Amanda N.}",

note = "Funding Information: Research reported in this publication was supported to B.K.E. by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number K12HD055887 and to A.D.S. by R01 CA154460-01 and U01 CA176067-01A1 grants from NIH, the Deborah Bunn Alley Foundation, the Tina Brozman Foundation, the Discovery to Cure Foundation, the Guido Berlucchi Foundation, and the Stand-up-to cancer (SU2C) convergence grant 2.0 to A.D.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2020",

month = feb,

day = "1",

doi = "10.1097/GCO.0000000000000599",

language = "English (US)",

volume = "32",

pages = "57--64",

journal = "Current Opinion in Obstetrics and Gynecology",

issn = "1040-872X",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies

AU - Erickson, Britt K.

AU - Zeybek, Burak

AU - Santin, Alessandro D.

AU - Fader, Amanda N.

N1 - Funding Information: Research reported in this publication was supported to B.K.E. by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number K12HD055887 and to A.D.S. by R01 CA154460-01 and U01 CA176067-01A1 grants from NIH, the Deborah Bunn Alley Foundation, the Tina Brozman Foundation, the Discovery to Cure Foundation, the Guido Berlucchi Foundation, and the Stand-up-to cancer (SU2C) convergence grant 2.0 to A.D.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Purpose of reviewThe purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers.Recent findingsApproximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated.SummaryHER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.

AB - Purpose of reviewThe purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers.Recent findingsApproximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated.SummaryHER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.

KW - biomarker

KW - human epidermal growth factor receptor 2

KW - ovarian cancer

KW - uterine serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85077226015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077226015&partnerID=8YFLogxK

U2 - 10.1097/GCO.0000000000000599

DO - 10.1097/GCO.0000000000000599

M3 - Review article

C2 - 31833974

AN - SCOPUS:85077226015

VL - 32

SP - 57

EP - 64

JO - Current Opinion in Obstetrics and Gynecology

JF - Current Opinion in Obstetrics and Gynecology

SN - 1040-872X

IS - 1

ER -